HC Wainwright Forecasts Fractyl Health FY2030 Earnings

Key Points

• HC Wainwright forecasts FY2030 EPS of $0.79 for Fractyl Health and maintains a Buy rating with an $8 price target, versus the current consensus EPS of ($1.61), implying a significant projected turnaround.
• Fractyl shares trade around $2.18 with a market cap of about $298.75 million and a negative P/E of -0.95; the company last reported Q3 EPS of ($0.35), slightly missing estimates.
• Analyst coverage is mixed but tilted positive with four Buy ratings and one Sell, giving a MarketBeat consensus rating of “Moderate Buy” and an average price target of $7.40.

Fractyl Health, Inc. (NASDAQ:GUTS - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Fractyl Health in a research report issued to clients and investors on Monday, January 26th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of $0.79 for the year. HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Fractyl Health's current full-year earnings is ($1.61) per share.

Other analysts have also issued reports about the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $8.00 price target on shares of Fractyl Health in a research note on Friday, December 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fractyl Health in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $7.40.

Fractyl Health Trading Up 4.3%

Fractyl Health stock opened at $2.18 on Tuesday. The company has a market capitalization of $298.75 million, a price-to-earnings ratio of -0.95 and a beta of 1.62. Fractyl Health has a 12 month low of $0.82 and a 12 month high of $3.03. The business's fifty day simple moving average is $1.99 and its two-hundred day simple moving average is $1.52.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01).

Institutional Investors Weigh In On Fractyl Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd purchased a new position in Fractyl Health in the second quarter worth approximately $181,000. Woodline Partners LP increased its holdings in Fractyl Health by 47.2% in the first quarter. Woodline Partners LP now owns 516,921 shares of the company's stock valued at $615,000 after buying an additional 165,786 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in Fractyl Health by 143.3% in the fourth quarter. FNY Investment Advisers LLC now owns 48,650 shares of the company's stock valued at $107,000 after buying an additional 28,650 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Fractyl Health in the third quarter valued at $81,000. Finally, Scientech Research LLC purchased a new stake in Fractyl Health during the 3rd quarter worth about $49,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.